In the treatment landscape of hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, cyclin-dependent kinase (CDK) inhibitors have emerged as one of the most transformative targeted therapies over the past decade.Representative CDK4/6 inhibitors such as Palbociclib, ...Learn More

In the field of oncology, anti-angiogenic therapy has become one of the most important treatment strategies. Among these approaches, drugs targeting the Vascular Endothelial Growth Factor (VEGF) pathway are widely used in the treatment of various solid tumors as well as ophthalmic ...Learn More

By:DengYue International Business Division The development of targeted therapies has significantly transformed the treatment landscape for many driver gene–positive malignancies. In diseases such as EGFR-mutant non-small cell lung cancer (NSCLC), BCR-ABL–positive chronic ...Learn More

In recent years, Antibody–Drug Conjugates (ADCs) have rapidly emerged in the field of oncology, serving as a crucial bridge between traditional chemotherapy and targeted therapy.With their dual advantages of “precise targeting” and “potent cytotoxicity,” ADCs are widely ...Learn More

By:DengYue International Business Division With the rapid advancement of precision medicine, targeted therapies have become one of the most revolutionary treatment strategies in oncology. As a professional pharmaceutical wholesaler officially authorized by the Hong Kong ...Learn More